ZNF32 and in situ carcinoma: Moreover, to determine whether the ZNF32 expression profile could be used to predict the responses of patients to chemotherapy, we analyzed ZNF32 expression in 37 of the 52 samples from patients who had received CIS-based chemotherapy and whose responses to chemotherapy were known.